Clinical Trials
13 trialsNCT05311618 2024-04-01
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Phase 1 Unknown
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT05223218 2023-07-03
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
Namida Lab
Unknown
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown
NCT03934827 2022-08-11
MICROBIOME
Imperial College London
Phase 1 Unknown
NCT05180851 2022-02-01
YSCH-01
Shanghai Fengxian District Central Hospital
Phase EARLY_PHASE1 Unknown
NCT04523116 2021-10-05
VALTIVE1
University of Manchester
Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT03517332 2018-11-20
Circulating Tumor DNA Exposure in Peripheral Blood
Quantgene Inc.
Unknown
NCT02366546 2018-10-24
Investigator Initiated Phase 1 Study of TBI-1301
Mie University
Phase 1 Unknown
NCT02457650 2016-08-03
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Shenzhen Second People's Hospital
Phase 1 Unknown
NCT00553683 2014-01-14
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Unknown
NCT01584115 2012-04-25
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
Instituto de Investigação em Imunologia
Phase 1/2 Unknown